uid stringlengths 32 32 | question stringlengths 16 2.61k | answer stringlengths 7 8.6k | eva4b_label stringclasses 3
values | choices listlengths 3 3 | eva4b_label_letter stringclasses 3
values |
|---|---|---|---|---|---|
1f035e26d8d3a5bb916f311f7bf6a188 | Okay. So carbon versus alloy and then defense then is rich, in terms of your mix and then some of your spot increases that you put it in both SPQ and tubing over the course of late last year, early this year. Are those starting to hit their stride in the second quarter, I would presume you didn't get much given your le... | Yes, on our base price quarter over quarter we recorded, we saw about a 6% increase overall. but we -- the price increases that were announced earlier in the first quarter are taking hold in the second quarter. So we do expect price improvements going forward. | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
fd4f14ff504b571ebbf81979fd885f3e | Okay. And then you have completed it appears your consolidation of Harrison and the Faircrest did you have any frictional costs in the first quarter in your results that you didn't call out. I know you pulled some stuff out of the numbers to get your adjusted results, but it -- was there anything in the results that yo... | Yes. There were some MRO and spares type of activity that we had to take charges on in Q1 that won't repeat itself going forward. | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
8856e11e66ca289de82c2e940a2ba719 | Were those pulled out then and -- because I know you did make a series of adjustments in your results. Were those still in the results despite the exclusions, that's what I was just trying to figure out. | Yes, Phil the majority of that was excluded, both asset writedowns as well as the supplies writedown those were excluded from our non-GAAP results. There was a smaller amount of alloy raw material adjustments, as we shifted all of our extra raw materials over to the Faircrest location that impacted Q1, but not raw mate... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
5e1b0db629bb2cbc291a652dcd4ddcd3 | Okay, Kris. And then -- I appreciate that. And then last one for me is net working capital. And clearly, you've got continued inflation in raw materials, better demand levels. What should we be thinking about in terms of net working capital over the balance of the year? Thanks. | Sure. Phil, I'll take a shot, primarily in the second quarter, the EBITDA growth that we commented on, in our guidance in the higher volume, should be a positive driver of cash flow in the second quarter. We do have some potential working capital build for receivables given the higher sales prices and higher volumes th... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
23f940d492376665b5de484d83a03be0 | Can I squeeze in one more here, just for housekeeping purposes. I think the bottom line number 55 million, 56 million from memory, how much share count in Q1. I know that probably did include some convertibles. What is that number on a pro forma basis, as we look ahead when you include the convert pay down. | There is about 3.2 million shares associated with the 2016 converts that are due in June of '21 -- first. So you would expect that 3.2 million to come off that total of share count, you mentioned 55.7 million. There is some additional shares for equity based compensation that's dependent on stock price and other things... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
71cf02369c3840e15750a6faa48a93ba | I apologize I jumped on the phone call little bit late, so I hope I'm not redundant here, but I mean, great performance in the first quarter and good outlook for the second quarter. How should we think about sort of the effects of inventory profits flowing through the first quarter of EBITDA and second-quarter outlook?... | It's a little tough, Justin. I mean we're turning our inventory quickly. All the working capital practices that we put in place historically are continuing, especially on the raw material side. So we don't have a lot of cheaper raw material sitting in there, it's current purchases, pretty much and trying not to, too ma... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
c697daf6fa4892ba43a8f6923b83a73b | Okay. And then just a reminder, I guess for us. Now that you've consolidated at Faircrest, what's sort of the maximum level of shipments that you could do on annual basis, assuming that you're sort of producing for the level of shipments? | Yeah. So based on the nameplate capacity of 1.2 million that was basically net out about 900,000 tons of shipments per year. And that can vary based on mix slightly. but I would say that's a good number. | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
68fa95040b50070379b36423cf49c39d | Okay. And just remind us as well. I mean you're on track to do about 400,000 tons of shipments in the first half. I mean if normal seasonality takes effect. I assume you would annualize that at a little bit less than 400,000. But if there is any just remind [Technical Issues] seasonality in the second half versus the f... | Yeah. So the seasonality really occurs in the fourth quarter based on what we see and that's typically driven by the holidays as well as year-end inventory reductions that the customers take to manage their inventories for year-end. Typically we see that historically it's been about 10% to 15% less than the prior quart... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
3df5204fa00ea7290e21e199612f7cd2 | Okay, that's helpful. And is there any sort of optimism toward energy or is it sort of -- so into your small contributor, your shipments forward for the future? | Yeah, I can tell you what we're experiencing is the fact that we have seen a pretty decent increase in activity in regards to inquiries but that hasn't necessarily translated to orders. The orders that we do are the slight increase in shipments to the energy market is predominantly driven by inventory gaps were require... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
56acca7e13008939070e09cdd0a812c4 | Maybe I could just start with the cadence of the sales rep hires. In the last couple of years, you've almost doubled the sales force, and the expectation is to grow, again, here by about 20 reps or so in 2020. And I guess the question is really around where you see it ultimately heading? Will there be a period of time ... | Well, I think we are slowing the rate of addition of reps starting this year. And I think that the size, the ultimate sales team will depend on as we scale and improve the productivity of the reps with the size of the territory that they can maintain growth, and continue to build their business. So as we've talked abou... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
43b6f55afc93cb74212d35844bb2ec11 | Okay. When we -- you put a finer point on it. So I think one of the things it becomes difficult to parse out from the numbers when you're adding sales reps is that the piece that you are, is to see any change in the productivity of the sales reps, depending on how you calculate the average number of reps. The productiv... | So what we've assumed in our guidance in 2020 is relatively flat productivity and not jumping ahead of that. I think, again, we're piloting some things that I -- that would have the potential to improve that. But until we see it, we're not baking it in. So at this point, the assumption is relatively flat productivity p... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
f10132acbdfef78ef05bc6d5c07352a4 | Okay. And maybe just one last one, just on the mix of revenue. Is there anything you can give us in terms of Avance versus the other products, the AxoGuard family of products, where you're seeing most of the growth at this point? Or is it relatively well balanced? | Its relatively well balanced. Avance remains a little over half of our revenue. That's been very consistent over the years. So we see growth across from -- across the board. But, again, Avance is a significant contributor with over half the revenue and growth. | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
25552b70d682b1658b8f1b715f7e1ace | The -- I appreciate that the guidance reflects an attempt or you're refocusing a little bit more heavily on your core trauma and some of the sales, the -- some sales force realignment that have been in the works here to do that and optimize the selling organization. I'm just curious, though, could you talk about what c... | Yeah, we don;t break out each of the segments. I think both breast and OMF have a small -- a relatively small base, but have a good opportunity for continued growth. And we've seen continued growth from both of those segments, when we look at their overall year-over-year performance. So we anticipate that both of those... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
39ae1a687cac892821cadcf87d32b732 | Got it. And Karen, just as you kind of look at, then reevaluate the things that are happening in your markets versus the things that you feel like need to be reshuffled internally and you had new sales leadership, which maybe gave you a fresh look or an opportunity to take a fresh look at some things, and that may be f... | Yeah, we have -- we obviously look very closely at the potential and opportunity we see at the account and at the territory level for all of our reps, and one piece that we've added into the disclosure. So, we've put here -- that we started reporting last couple of quarters, is that 10% of our revenue, excuse me, 10% o... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
f316bec3f25aee4c059345ca27a2b793 | Got it. One more, just -- is there a price increase assumed in your outlook for 2020? And how much? | Yeah. Yes. We take a price increase or have taken a price historically in the first quarter. We are doing that again. This year, we've assumed, however, that the price increase will be low-single digits, just with anticipating that as we get into larger and larger accounts, that there'll be more price pressure for some... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
f326b893dc2b89502702dfff130f1761 | Hi, this is actually Dan on for Dave, thanks for taking the questions. So just first off, -- hey, how was going? -- so first off, you mentioned operating margin should see some improvement in 2020. So we were just wondering if you could give us any color on where you expect to see this benefit on the P&L? And how much ... | Well, I think I don't quantify it, but I'll certainly indicate that we're going to continue to make investments across the organization. But we've been moderating that spending growth. You will see leverage in G&A certainly, and sales and marketing across the year. Well, you've seen us continue to grow the R&D line. Th... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
15bab98466b70f651e2ca04eef9963f2 | Okay, great. That's helpful. And then just a follow-up. Touching back on the splitting of territories, long-term this should drive productivity improvements. But, could you just give us an idea of the amount of time it takes to transition a region through a split, as well as how long it takes to see productivity ramp b... | Yeah. When we talk about bringing in a new rep, we still see that we assume 9 months to 12 months before they really started get effective and start to see that ramping. So the rep who has been with us for a while, and it's keeping a portion of the territory, there'll be a short-term disruption as they split things, an... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
d86e818dd57a237e6411aa1f7de1a675 | Hi, thanks. This is Sam on for Ryan. Just to start out with, I know it's early, but first quarter with updated CMS reimbursement for nerve repair, can you kind of characterize any change in usage patterns you're seeing based on this? | Yeah, it's still too early to see anything. Remember, Medicare is a very small amount of traumatic injuries, traumatic -- trauma happens to be a young persons injury, more often than it is anybody who's in the Medicare ranks. So we don't see a tremendous impact at this point. It's more around the commercial payers star... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
e0a5f0cc7f898bb9a9da17f442a6a8a7 | Okay. And then on the gross margin lines, year-over-year decline there. How should we think about this going into FY '20 and can that contribute to that operating margin expansion? Or should we expect to see pressure there? | Yeah. No, we said in my -- our prepared remarks, we do have some increased processing cost. As we get larger, we've got additional costs in our current production facility. And in addition to that we had a one-time event in the quarter, where we ended up having to take some additional reserves on inventory primarily on... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
7db8b970688d5013779180c38ffd994b | Great. Thank you very much for taking the question. So I just wanted to follow up just a little bit on some of the commentary around the 10% of accounts or the 80 accounts that represent the 35% of revenues. Just maybe if you could give us some historical context there as far as how long it takes some of those accounts... | Yeah, this measure of -- we noticed that this measure of the top 10% of our accounts yielding 35% of our revenue has been in place for a number of quarters. So that's not something that just popped in fourth quarter pretty much through last year, and into the year before we saw the same sorts of trends, which does mean... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
af710cb0c166291be65478b4012a55ca | Great. That is -- that's very helpful. And then, I just wanted to circle back on one of the previous questions regarding sales force productivity and just kind of what's assumed with respect to the guidance this year? Maybe just also you provide a little color on -- you've made some significant increases in the sales f... | Yeah. I think we've done some very good things to give the new reps that we're hiring a solid foundation in nerve repair. And so we've increased our -- both our clinical training as well as our sales direction on how to sell in nerve repair. We're very technical sell, but we still need to be able to approach surgeons a... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
b7bce807aecdbee212edc4adae3a2a32 | Could you talk a little bit more on the cloud? Maybe if you can quantify a little bit more of the signs that you think you can provide your customers with flexibility? And just maybe what's competitive intensity like for you within cloud now? | I think the -- when we talk about cloud, it's not about TCO reduction only. I think that when we look at the holistic value moving to the cloud, it's much more beyond that. You are coming to a much more resilient environment, much more secure. Time to market is much faster. Ability to come with new innovation is much f... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
2a61dec564a68a64491f80f6e576dfe8 | And can you talk about the competitive intensity, like, who do you compete with these products? | I'm trying to be extremely humble. And I can tell you that when you talk about existing Amdocs customer, we are by far the market leader and the first choice for all our customers. Because if you -- I think that the migration to the cloud in an Amdocs of customer that's actually moving from one platform from Amdocs to ... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
7e81e47a409a526afc36f33434329c49 | I have a question on the environment. Some of the questions we're getting about Amdocs is what is the historical correlation between any economic slowdown and the business you have with customers. So if you can address things like in previous downturns have you seen cancellations or pushouts of orders, or what's the co... | Hi, Tal. I will start and Tamar will add if I forget something. If I want to simplify it, we have two main activities with our customers. The first one a very large one is all the managed services operation on the -- on our current systems. These are mission-critical systems. It is not something that you can stop or ho... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
8040f40b5edd928abf4b46d791836bd4 | The second question -- final question is, what do you do with your hiring? Are you -- can you talk to us about kind of hiring this year? What are your planning for hiring? Is any plans to slow down just to address maybe economic uncertainty, or do you continue to hire according to plan? | So we are continuing to grow our staff, and frankly speaking, I prefer that this growth will come with lower attrition and less people that we need to hire in order to achieve this net growth, but the bottom line is that we are growing our staff. We are very focused while we talk about the global picture also to balanc... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
fe33c7bd398af4462c9305391fb892c2 | So as you said, you seem pretty well positioned for NII growth for the rest of the year. But, Seth, just building on your comments just now, how are you thinking of the ramp of core yields through the rest of the year, if the forward curve plays out with the numerous rate hikes that are expected from the Fed and then t... | Yes, sure. A couple of things on that, Crispin, thanks for the question. One is, when I think about it from a Q2 perspective, we should note that the majority of our originations occurred in the first quarter toward the back end of the quarter, as well as the rate increase by the Fed of the 25 basis points was only eff... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
5f291ef84f3f638699794fb2cd9c02a6 | Thanks. That's very helpful. And then just looking at your tech and life sciences exposure, are you inching one way or another for new fundings? I know, it's been a tough environment for tech with higher rates, at least in the public equity markets. And I know I think Scott mentioned earlier in the call that you had mo... | Sure. Thanks, Crispin. The key operative word for us is balance and diversification. We've often said publicly and in some of our private conversations that in periods of volatility, the focus for us is on maintaining balance and diversification.
And that's exactly what we're trying to do now. Our target exposure righ... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
0a2149939e3100e27853ac597cdafb7a | Hi, good afternoon and thank you for taking my questions. In your prepared remarks, you mentioned that only one debt investment is on non-accrual, which is great. But could you provide some insight on the two debt investments that came up non-accrual during the quarter? | Sure. One was the legacy Sungevity Solar Spectrum investment and that may be a name that rings a bell for some of those that are on this call. That was a company that went through an insolvency proceeding several years ago. We restructured that debt.
We ended up funding the NewCo coming out of it, and that company has... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
6c1f642948c926fa81c12ee373abf307 | OK. Appreciate the color there, Scott. And then last quarter, I believe you mentioned targeting regulatory leverage north of one times. As a quarter end, you're well below that at 0.88 times.
Just curious if your target leverage range has shifted at all given the current backdrop. | No change in it. We remain at a target ceiling of 1.25 to equity on a GAAP basis. And we do have the ambition. It should prepayments continue to remain low of continuing to drive that ratio up a little bit closer on a regulatory basis to one to one. | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
9bda8ea31cb0c7f47ce92bc44dc2efa0 | Hey, everyone. Good afternoon. First question on the Advisor, are you considering or undertaking more than one multiple fund lines and what -- if so what strategies would the new ones be in? | So we currently are managing two distinct parallel funds in the private fund business. We are certainly beginning now to think about what's next in terms of potential funds down the road, but there's nothing imminent and there's nothing near term to discuss the two private funds now very consistent with the strategy th... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
66139f274d940d1d0211cb43ac6eefff | Sure. That's helpful. Thank you. And is there any -- I think that you're hit a lot on your commentary, which is helpful, but sounds like, everything's pretty healthy holding up well in terms in yields and all that. Is anything or is it comparatively more interesting to you anywhere in the public stock markets, where a ... | Yes. So not on the equity side, we continue to have about 6% to 7% of our investment portfolio in equity securities. That has obviously come down proportionally as the markets have declined over the course of the last six months. We will opportunistically make direct equity investments in some of our public borrowers, ... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
6399640b0d155cfbbfe9ba3b120cf1b7 | Hey guys, apologize. If you comment on this, I did miss the front end of the call just because it got, we're juggling earnings. But in terms of timing of you had a lot of deployments in the quarter, but were they back weighted or anything you can comment in terms of the timing of the deployments. | They were very strong investment activity in the quarter 650 million of commitments, 352 million of fundings, approximately 55% of the fundings in the quarter occurred in the month of March. So very heavily weighted toward the backend, which obviously will provide some significant power for Q2 and the go forward period... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
039db51aadce0737613814559520ef9d | OK. Helpful. And then understand how rates will affect revenues and earnings. How do you think rates up a couple percent from here, does that start to slow repayments, do you think or early payments or is there you can't -- it's really unpredictable in terms of behavior there. | I think the prepayments are just very difficult for us to predict and we've talked about that on a pretty consistent basis. I think the one theme that we absolutely can speak to is that over the course of the last several months, we've seen a significant change just in terms of sort of the mentality of boards and compa... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
ebdfd9c114297fcace20de9c7ce4ad3d | OK. And just any changes in kind of your emphasis or focus on different sub sectors given inflationary trends and how that might impact, how industries work? | Sure. We tend not to want to talk about moves that we're making. Just given that we only want to be kind of cognizant of what others are doing. What I would tell you is that and we spoke about this in our prepared remarks.
We have absolutely over the course of the last two quarters begun to position the portfolio into... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
c7d2176491fe67b70e87148cb01f45e8 | Good afternoon. First question, I just wanted to focus on was just the core yields are spread that, that you guys are anticipating throughout the year. You obviously talked about a lot of volatility in the marketplaces today. I think increasing the attractiveness of potential borrowers to access venture debt, which I t... | Sure. In terms of the core yield, the guidance that we gave for Q2 is consistent with the guidance that we delivered for Q1, which is that 11% to 11.5% core yield target. We didn't mention this, but toward the backend of 2022, we certainly would expect to be on the higher end of that yield guidance from a core yield pe... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
2939038e9f5db4291377852e266c2f4c | OK. That's helpful commentary. One thing I also noticed in your press release, you guys have the debt portfolio composition breakdown and it looks like your first lien senior secured loans have dropped from about 83% of your portfolio a year ago to about 73% today. Can you just talk about what's kind of the driving fac... | Yes. So, yes, as you pointed out right now about 73% of the portfolio is in true senior secured first lien debt that is down slightly from where it was over the last several quarters. And that is directly correlated to what we talked about in our prepared remarks in terms of what we've been intentionally doing over the... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
edcd66e7a35f689201bf6e8ef48c67df | OK. That makes sense. And then just one last one that I had, you kind of lay out on Slide 40 of your deck, the venture capital fundraising and investment activity. And it was interesting to see that that venture capital investment activity was down for at least on pace to be a down year relative to 2021, which is not s... | Yes. I think it's all from our perspective very positive and very much expected. And it speaks to a very healthy and vibrant VC ecosystem. Fundraising continues to not only be strong, but actually to exceed what we saw in 2020 and 2021, $74 billion of venture capital funds raised in Q1 relative to 132 billion raised in... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
d003e769426466ee6c0fca2d4e5a1aa6 | If we look at Slide 10, I think about your comments about the, you know, discussions you're having with your automaker customers is potentially getting some recoveries or greater recoveries. I'm just curious where the greatest opportunity is, because, I mean, you traditionally have, you know, metals market, you have pr... | Yeah, John, just to maybe -- this is Chris. Good morning. Just to maybe frame up that $28 million, about two-thirds of that relates to net material costs that we've increased in terms of inflation. And we reset a lot of the purchasing prices with our supply base on the 1st of January. The balance of that or the remaini... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
31c97a48f55d08a3c344c1b128be2ab7 | OK. But I mean -- I'm sorry, I mean, usually, there's kind of a takeaway on this stuff. So, you think there's a reasonable portion of the 20 million is going to be recovered in the coming second and third quarter. I'm sorry -- is that what you said, Chris? | Yeah. On a perspective basis. As we have reset a lot of our pricing with our supply base, we are in with our customers having active discussions on compensation-related to some of those increases that we've already begun to experience here in the first quarter. | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
1223f9be6d8cdea136689d658cdb5601 | OK, that's encouraging. And then just a second question on Slide 4. You know, I mean, obviously, you could argue that the Geely contract is kind of outsourcing of traditional products, but, you know, it kind of in that vein. So, just curious, if you think about sort of these new quotes that you're winning business with... | Yeah, John. This is David. You know, first and foremost, you know, our objective was to try to secure our next generation business on our traditional or conventional product. We've made tremendous progress on that, as we've announced, you know, previously in earlier calls. So, we feel real good about the cash generatio... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
a2953ec9d0ff0ef8580088ae705aa4e2 | As we go about model, which is on Tekfor, as we go about modeling that acquisition, what can you tell us at this stage about the margin profile of that business? And, you know, it was announced in the press release highlighting the pivot toward electrification? I understand you brought into your electrification product... | Yeah. Hey, Brian, this is Chris. We did disclose in our press releases just in terms of framing the size of the Tekfor acquisition from a revenue perspective. Last year's revenues for Tekfor were approximately 285 million euro, and we're looking to close on that here in the second quarter. We have not disclosed specifi... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
54dae006bc99aa30d66596b38e06e679 | OK. Yeah, it does. Thanks. Maybe, just finally, still on Tekfor, you know, I recall, when you purchased MPG that they were a supplier to you also. And so some of those sales became like intercompany transactions and with the benefit, in the case of those sales, to EBITDA instead of -- or EBITDA margin, or EBITDA instea... | Yeah, Ryan, this is David. A small percentage of their revenue comes from American Axle, although, they are a very good supplier to us out of our Brazilian operations. As Chris indicated here, we're going to continue to use our operational excellence and really focus on the synergistic opportunities to drive margin enh... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
873c4e0eb19d18553e07fa3aee8524ec | Chris, I was wondering if you just help us a little bit on the updated guide versus prior. I think, previously, you were looking for metal markets to be $150 million to $200 million plus, and call it about a $30 million negative on EBITDA. What's the updated contribution to the new guidance from that on both the top li... | Yeah, from a metal market pass-through perspective, Joe, that would still remain very similar. And you can see that run rate flowing through our first quarter. So, from a metal perspective, not a lot different from where our guide was 90 days ago, if you think about why the top end of our range from, revenue is down, t... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
4daad5091d8aa96842742d75c564a4c5 | OK. So, the reduction is pretty much volume-based. I guess, if metal markets -- this is a dangerous statement, but if they actually hold you from spot, is there still an impact into '23? Or would '23 be more neutral on both counts? | Yeah. If metal holds at these levels -- and as you know, Joe, they reset every 30 days -- We saw a metal start to trail down in the first quarter, and then they've spiked up in May, for example, obviously very difficult to predict. But if they hold at these levels for the bulk of this year, on a year-over-year basis, s... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
ed538f5bf706fb81f0b18c5738c39233 | Yeah. Perfect. And then just finally, you know, David, maybe even sort of ties in a little bit to some of your sustainability comments. I guess, just functionally, when you are selling a, what's called, a 3-in-1 or an electric drive unit that has a motor, right? I think, you're not doing the motors, but the motors clea... | A couple of questions within your question, so let me just kind of walk my way through this a little bit here is, you know, clearly, what we're going to do is from a motor standpoint, inverter standpoint, we're buying some of those, you know, today. We have agreements in place with those customers, you know, or those s... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
e0ad637a6cd3bc45f92922c0d7a463cb | Hi, thank you for taking the questions. I'm sorry if I missed it earlier, I think you may have mentioned it. But just an update on your cost guidance, which was 40 million initially. And maybe you could just talk broadly about the types of costs that you're seeing, be it labor freight, we know that you're very energy-i... | Yeah. Good morning, Dan. This is Chris. Yes. The guidance that we released in our previous earnings call did show a net $40 million increase for purchased materials, Obviously, with our updated guidance you see here today, that has significantly increased in terms of the net cost associated with that. And as we mention... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
a0a866ab7da34f5999ddb7eae998ae4c | Great. And even if some of this cost is sticky, and even though we just assumed that inflation is what it is, there's no reason to believe that your incremental margins on any volume recovery wouldn't be similar to what they've been in the past, call it, that 25% plus contribution margin. Correct? | When you think, just pure impact of volume changes, you are correct. | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
f808cd9cd6e839afd1c26d7793bcdd42 | OK, great. And then just as a second question, given it's a more uncertain environment, and the goal of the timeline of reaching 2x net debt-to-EBITDA is, you know, probably pushed out somewhat given the macro volatility. How does the balance sheet -- how did the playbook change for a balance sheet action? Clearly, you... | Yeah, from a balance sheet perspective, look, I think our operations have been set up, and we continue to operate them to generate strong cash flow. We continue to take action on the gross debt side of our balance sheet, we paid additional debt down in the first quarter of this year, in addition to announcing our Tekfo... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
5b5da3fe861eaad0a6500610980ae318 | If I could just ask about what is built into your game forecast for 2022 for bookings that you shared with us. And how does that potentially change if India was to come back on track as an earlier than expected date potentially. | OK. Thank you, Piyush. So the voice quality wasn't very good, I'll try to answer your question, if it's not clear, please let me now. In terms of the game guidance, as we shared in the earnings that given the opening of our markets and the trends we're seeing and also some unexpected government action we are facing, we... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
6e42c8d7962cb4369eba2249b3baa350 | First of all is, can management talk a little bit about your view on the 2022 GMV growth? And the second is, can the management help to sort of break down the rough mix of Asia and new markets in terms of EBITDA loss this quarter? | Yes. So we don't give guidance on GMV, but we did give guidance on GAAP revenue for e-commerce. We believe that it reflects our view about the potential growth rate. And I also mentioned that in terms of the take rate increase, there will be -- while we will continue to increase take rate, the pace will be moderated an... | fully_evasive | [
"direct",
"intermediate",
"fully_evasive"
] | C |
b7e08aa4187951bc02779c64f6b4a061 | Firstly, on e-commerce, your guidance to achieve positive adjusted EBITDA in your core markets, this would be driven by what key factors? Is it higher take rate or lower sales and marketing? And any color over there would be helpful. And if you can throw some light on the competitive landscape in core markets? | Sure. In terms of our e-commerce cost of EBITDA in Southeast Asia and Taiwan, this is as a result of both the higher take rates and also cost efficiency as we scale. As we always mentioned, the platform, the marketplace model that we are pursuing enjoys a strong silo effect and the economy of scale as we continue to gr... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
0e55d9e301965653f67c6bddf3d089c7 | So, I have two questions. And the first set of question is regarding the -- these suprachoroidal microinjector program, AAVIATE trial in wet AMD. So you mentioned that you already dosed a patient. Just wondering how many patients have already been dosed? And is that right that all the patient you've dosed so far you ha... | Yeah. So AAVIATE, as we disclosed today and as you mentioned, it is true that we've not seen any evidence of inflammation so far. It is still early in the trial in terms of a number of patients treated. You also asked that question. We only did just announce the dosing of the first patient in early September, so not th... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
84178dae59f9426554e42f6e24712406 | And then, second question is regarding the MPS II. Just wondering if you can give a little bit more color regarding the year-end '20 update. What type of data in terms of both -- also patient numbers and type of data that we will see? | Yeah. And just quick -- thanks, Steve, for the complete answer there. And on MPS II, Gena, just quickly, we do have plans for an update before the end of this year and very pleased to have announced today two additional patients enrolled at the 6.5xe10[Phonetic] dose level under this expanded protocol. What we have is ... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
2bc184fecc549954dfa620556affa26d | So my first question is on 314. Do you have a sense from your physician interactions what an acceptable frequency of rescue VEGF injections could be with 314 for clinical adoption, particularly taking into account the three-month dosing for Beovu and six months for Lucentis PDS? And I know it may be a bit premature con... | Sure. Steve, I'll let you swing back to maybe some of the physician interaction in terms of intervals of treatment. Alec, thanks for the question. I mean, we have been -- we're moving into pivotal phase of development and we have started to engage. The entire system in discussion is about the value and need around chan... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
9d5bcd4c48a5738df9e8b7b4a2615441 | The first is on manufacturing, given that you have internal coming online, which people recognize have certain advantages. But we've also heard that it's not just having a facility or footprint, it's the processes analytics. So could you talk about what you're doing to sort of have a best practice on those dimensions o... | Yeah. Gbola, thanks a lot. I'm glad you went there because it's a -- well, I think, it previously has been a subtle but maybe less and less subtle point for investors on these areas. And I would say that, even with our existing supply chain and the strong collaborations we have with bulk manufacturers and final fill fi... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
1484cfe10b8b92d885b441d78b6859e7 | I have a quick question on your CLN2 programs. Can you please talk about the status of the programs and what needs to be done before you file for the IND in 2021? | Sure, Kostas. Just at a high level, let's see if Steve has anything else to add. We're guiding here to milestones that are very soon with respect to those two programs. So in the case of both, we are really having completed the preclinical study evaluation phase and readout phase, and keeping in mind that certain thing... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
5a61dd5e55af77cf3360cbfd8fa5d326 | So now that the pivotal 314 trial is set to start in the first quarter of 2021, we are hoping to get some color on the trial design. Have you received any feedback from the FDA regarding the pivotal endpoints, what the control arm would look like, duration of endpoints or any other aspect of trial design? | Hey, Rick. Thanks. No, not that we're updating today and we will plan to update that at the beginning of next year when we talk about the initiation of the study. So, we continue to guide to the fact that we think moving into pivotal phase of development in retina has some familiarity with the agency for different type... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
1f7f75d4000f7b3952e428691d2f2e2a | We just wanted to ask if we could have an update on the IP dispute going on between you and Passage Bio, as well as Sarepta? | Hi. Lisa. Thanks a lot. We don't have any specific updates to provide today. We have provided information previously on -- or I guess provided feedback with respect to our interest in making sure that people that are working with intellectual property and science that overlaps with our NAV Technology Platform are under... | fully_evasive | [
"direct",
"intermediate",
"fully_evasive"
] | C |
7c72b26a279574328fdf576aeaf173d8 | First of all, congrats on the $80 million payment on Zolgensma. I get asked a lot about how long I should model the royalties from Novartis. So, I've noticed that you do have patent term extension and supplementary protection certificate as a process ongoing in multiple jurisdictions, given the additional approvals. Wo... | Hey, Gbola. Thanks. 101, I like that. AVXS-101, that was clever. The work that we're doing around patent term extension, I think, I mean, all of you in the -- on the sell side, I think I understand much about the processes on the biologics side in particular. We have approvals now that are occurring, it started in the ... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
1f179f0e9586c79786f28a687520ea5d | I was hoping we could start kind of high level with CCM, updated perspective on where the industry is in the replacement cycle and specifically whether you think you may be approaching peak at this point? | Well, on the replacement cycle, I think we've showed you and others the reroofing demand that was created with roofs that were put on, in the past 20 years plus, and are coming due. We see that accelerating at least for the foreseeable future. And so I think for the reroofing cycle, we are nowhere near peak. I think we... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
81788ffae59bb71c77cd4e03b940eb2b | Okay. It's great to hear. And obviously good price cost realization again in 3Q. That remains a hot topic. What is the updated estimate for 2019 benefit? | Yeah, Bryan. We're thinking 80 to 85 now as you know, raw material stayed lower than we thought, holding throughout the year, so. | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
ca6df1310412cf89e2027f126b66798b | Got it. And given current trends, would it be fair at least on a preliminary basis to think of 2020 price cost as flattish? Or should we anticipate given there are some continued benefit given the January pricing and still pretty cooperative commodity costs? | Yes, I mean, Bryan, we're not going to comment on 2020 deeply now, but based on where we are with the pricing, we did put out a pricing increase of 2% going into January. So that should help next year. And it's too early for us to call, it's going to happen to commodities right now. | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
f64b03293aaa033f33087f1d32bb60c4 | Could you just talk more about the two acquisitions announced last night, so Providien and Draka. I'm just curious, would you expect margins to be accretive to CIT segment profitability in 2020? Again nice improvement in the quarter on CIT. So just trying to figure out how those acquisitions will impact the business in... | Yeah, Bryan -- Neil, where we are now, I think it's a little bit too early for us to talk about that, obviously that will unfold as we sign and close on these deals. What I can tell you is that Providien you know they're an excellent company. They fit right into the the necessary areas that we had to continue to build ... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
9cc0962c3afa3b6750fedcb97a1e7cb1 | Okay. And then just specific question on Providien. I think some of the revenue is tied to aerospace and auto with its Dynaroll business. So could you just talk about how much of Providien's total revenue is non-medical related because it sounds like it's more of a medical play but just again curious on some of the Dyn... | Yeah. Again, I'm really hesitant to get into much detail prior to the close, but I would say that the vast majority, and the impactful part of the Providien acquisition, both from revenue and operating income perspective would be in the medical technology space. | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
b12d4e5a33760d41c493834a115939f3 | Okay, thanks. And then just one final one, Chris, as we're on capital allocation, especially as it relates to the M&A pipeline. Following these two deals, will you sort of pump the brakes, so to speak in other deals until you get these integrated? And then I guess just as a follow-up with regard to your appetite for sh... | Yeah, I think we continue to take the same position we have going into this. I think these will -- these integrations will go smoothly. We continue to look for any acquisitions within the building envelope, within the MedTech, within Aerospace, and within Fluid Technologies to expand that platform. So right now the pip... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
bdc3edfed874d9da978d009f2ad60060 | So maybe going back to the pricing question, just more of a cadence question. So are you kind of thinking about pricing kind of structurally different than what you have in the past where historically it's been very reactive to commodity increases. I mean, is this a situation now where you think every year you're going... | Yeah, Tim, I would say that in the past, it was almost pricing -- like you said very reactive and almost with a very broad brush just reactive in some big bucket in reaction to raw materials. We have worked over the past few years to really focus on changing that and really pricing to the value we're providing the mark... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
677af60dd091e8b8982e81f0e93c5787 | Okay. And is there any, as you've kind of gone through kind of an internal review, is there any areas in the portfolio that you think are very under priced relative to the market value? Or do you just think that the whole portfolio can kind of migrate higher over time? | I think that through disciplined approach and more systematic look at that through more sophisticated tools that we have now, we've been investing in. I think there is, while the entire organization has seen pricing this year and we've been really pleased with that. Even CFT and CBF have had pricing despite the headwin... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
21bf7d82385650f562afeb90877b479b | Okay. Okay and then just the last one on just labor, of contractors, is there, it's tight. I mean, is there anything that that scares you that at some point that the labor just, there's not enough labor for the market to grow much beyond a couple points? I guess I'm just kind of curious if there is kind of a structural... | No, I don't think so. And I think one of the things that it is tight. We seem to be -- we have a nice backlog of jobs. One of the things that it does for us and I'm encouraged by is it brings us back to the value proposition of CCM in some of the labor saving products that are coming out and we're seeing traction on th... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
e642181a7321aedc077ee9a40ca0b43c | So I just wondered if you could give us a sense of how far out your kind of visibility on the CCM business goes? Are we kind of into the middle of 2020? And also are the competitors going along with the pricing or is it too early to tell? | The first one, Joel. We have, we took the price leadership there on a 2% increase. And then we have seen competitors follow, not all of them, but a vast majority of them, which is a good sign. As far as looking at, we hate to get too far and project out into 2020. But I would say probably the same thing we said at the ... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
4267a5e138d0f1c3d48fd6ebdecc2d17 | Okay. That's very helpful. And then on the medical platform, is it fair to kind of guess that you're around the $250 million in revenue level? And is that, is that platform, much higher margin or noticeably higher margin than the overall CIT? | Yes, it is $250 million, just around $250 million, Joel. And we believe short term with purchase accounting and things going on that will be in line. But over the long term, it's inherently higher margin. | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
3ccd1dad8f96ea5722b651cdf122f546 | Question on CCM, the organic growth, 9%. I was wondering if you could maybe break out volume and price? | Yeah, Garik. As we talked about last year, we lapped the price in the third quarter. So price was relatively small part of that. There was some as we, we did announce some small price increases and, as Chris said, we're getting very strategic, but it was a very small part. | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
398a20ce960a40aaf675adceebbb534c | Okay, that makes sense. I wanted to ask actually about CFT, the outlook is calling for a sequential increase in sales. I think that was kind of expected, the 4Q was going to see an increase I think largely due to some new product introductions. So just wanted to confirm that that's the main driver of the sequential inc... | Yes, I would say Garik, that certainly new products. I think some some better alignment around the new acquisitions, obviously integration, as we get through some of that, then they pick up speed and we're certainly excited about what Ecco brings in the combination on the sealants and adhesive platform. So in essence, ... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
d35d4372849e6ab16e73c771aed624a0 | And I just wanted to ask you saw a deceleration in the macro environment for CFT and for CBF in that matter in the third quarter. Just wondering if you're looking out to 2020, will you need to take any additional cost actions in those businesses to right size, given the -- I guess weaker market opportunities? | No, I don't think so. I think the play for CFT is still and CBF has been longer term, I think that the investments we made in CBF has certainly paid off. Moving back to Medina, we've -- we think we're back on track there from at least from a profitability perspective, if volume does return then we're right back to wher... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
f6c2e37800870e0930b9e2db13730e29 | Wondering, so on CIT. It's been a while since you've done any acquisitions of kind of this magnitude like the two that you announced today. So I think one of the hurdles has been extensive asking prices multiples on any acquisition. So wondering what's changed there, have some of the multiples come back down to earth o... | Yes, I think what has changed, certainly multiples have not come down at this point. I mean, I think you're right, we would look at what's happening economy. I think they might, but both these are very, very different than maybe the last two acquisitions within the medical space. Draka Fileca is a really, really is ver... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
bf309a346d5ebb3bc02217d6b1d1fa25 | Okay, got you. And then we heard there was a tornado damaged one year CCM facilities down in Florida, a couple of days ago. So wondering -- heard it's an Insulfoam facility. So I'm wondering if you could give any comments there? Do you expect there to have any disruption or can you service you know from other locations... | Yes, I mean first of all, we're thrilled that everyone was safe. There was no injuries at all and terrible thing that happened in that facility. But overall impact on the quarter should not be anything, we don't see much going forward. We can, we'll have it up running pretty quickly and we believe we can ship in from o... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
77ccf36aaa4c074de8ca1daf20e66829 | Okay, got you. And then, on CFT, you mentioned that pricing was positive in the quarter and obviously, volumes were down quite a bit. So wondering if you're having to trade-off volume for pricing. I'm wondering how the competition is doing? Is the competition also have positive pricing and you kind of think you're perf... | I don't think we're trading any any volume on for price, I mean, I think this is a market that if you look back at the competitors Nordson, Graco and these others, I mean, pretty much end users. It's an ROIC sale and people are paying for value that is very tangible and returning to their bottom line and that's why we ... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
deca864af6a6957aab86738a271fbc3c | Hi. Good morning. So I've got a couple of questions. I mean first, with regard to, I guess, retail and just the comments that you made about the current environment and then which led you to lower your guidance for the balance of the year. I guess the question I have is maybe a little -- if you could elaborate further ... | So in Q1, we are overlapping the stimulus. And so that was definitely one of the drivers of our decline in Q1. And some of the stimulus money will continue to impact future quarters. But we are seeing a deterioration in the macro environment as I'm sure you've heard from other retailers. We've seen softness in consumer... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
0a054d37ba5d8ef466cc5ae249e021bf | And then I guess shifting -- the second question, just on the new -- the Belk relationship you're announcing. I think you've mentioned -- Chandra, you mentioned in your comments that the Belk stores are located in existing Conn's market. So the question I have is, are you -- with this relationship, are you basically ca... | Yes. So if we take a step back and look at what we're doing with the Belk relationship, one of the things that drew me to Conn's was our best-in-class supply chain for non-conveyable goods. Today, that best-in-class supply chain is mainly serving a narrow -- a pretty narrow market segment of the market. So my ambition ... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
36c27a1c2a26386ff0a8534b3b9ccfb8 | Hey. Good morning. Thanks for taking my questions. I guess just to stay on Belk for the time being. So if I heard you right, is that primarily targeting a fast and reliable customer and like, I guess, how much of Belk sales would you expect to be financed either in-house or LTO? | We expect Belk to be a high percentage of sales being the fast and reliable customer. So we will have the capability to offer financing to Belk customers. But out of the gates, we expect the majority of sales to come from cash and credit card. And if you think about -- if I could just add to that, Kyle, if you think ab... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
bd3d8470461083ecc6727b645bf59091 | OK. And then can you just give us a sense for expectations of productivity of a store-within-a-store versus a traditional Conn's store? | Yes. I mean we expect a store-within-a-store to be generally lower volume than a Conn's store. But the capex for a store-within-a-store is also much lower than what a Conn's store is. | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
45438644ab9014ec72578cadead73093 | Yes. OK. And then, obviously, you guys have a lot going on with the in-housing LTO, Belk, etc. But longer term, can you update us on how you envision your sales mix shift in terms of cash, private label, in-house and LTO? | So in terms of our core Conn's business, we don't see any type of major shift in terms of balance of sale. But if we -- the partnership model, if we do end up using that to drive a significant amount of growth, that is where we will see over-indexing in cash and personal credit cards. | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
83b0ece1638511d09db3fd8f4461591e | Hey. Good morning. Thanks for taking my question. One more on Belk. Just to clarify, so I guess, Belk, in terms of revenues, that won't come in yet in fiscal 2023. But I guess the expenses to ramp that up would be. So first, is that right? And is that one of the things that are maybe driving the lower -- sorry, the low... | So we're starting our Belk partnership in Q3 of this year. So we'll open 10 to 20 stores by the end of Q3. So we will see some revenue from the Belk partnership this year. But it is -- we don't anticipate Belk being a driver of negative profitability. And if you think about, Vincent, drivers of the margin change compar... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
aca553eac4a0cee74e7b4878981b8f65 | OK. That's really helpful. And then second question on -- so the credit segment performance was actually really strong this quarter. And I'm impressed that net charge-offs are actually down to 11% versus 15% last year and your spread was much higher than the 1,000 basis points that you guide to. And I'm wondering kind ... | Yes. Overall, the weakness in sales is really being driven from macro factors. Obviously, we want to be -- in a time where it's a challenging macro environment, we want to be appropriately conservative with credit. And so we're always making adjustments both to drive sales and to limit risk to our underwriting based on... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
117347c305b4dd3546e54acfeef8d3b0 | Jack, you just mentioned your -- your guidance in the first quarter same-store sales was up 38%. You're going to face some really challenging comps in the second half. I'm just wondering if you see any quarters where you might have like a negative same-store sales rate in order still to get to that mid-single-digit rat... | Yeah. I mean, we're -- it's -- we've -- we've spoken many times about the June quarter and the 44% comp that we have to go on top of. I -- I wouldn't say I'm forecasting to be negative in the June quarter but that's probably more a flat quarter compared to, you know, being up significantly this quarter. And -- and just... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
6fce9a01b264a9e53e9fd64863e12a37 | And then just as it relates to the acquisitions, can you confirm that all of the acquisitions were paid for in fiscal Q1, or was there any cash outlay in Q2? | Yeah, no. It was -- it was all in -- all in Q1. It was December, you know, the Tom George closed on the first of December and then Roscioli and Walker Marine both closed on December 31st. And so, all the cash was out as of December 31st. | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
a6caa14b5e5bc7cb55b8e731e6472a80 | Austin, you know, you're integrating three deals now. Could you just remind us all of -- of what you're integration process is? What do you like to achieve in the first -- let's say 100 days of in -- integration? And then, how stretched is your team today given you've got three integrations ongoing, you know, such that... | Well, I mean, you know, Tom Goerge Yacht was done on December 1. So you know, when we -- it was fully integrated on December 1 as far as, you know, the system and all that stuff. So you know, continuing on with Tom George, now it's just starting to get the processes of, you know, the CRM process. You know, after not, y... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
61039d07c35eba939902b820efd97116 | I just want to circle back on -- on the EBITDA guidance for a second. So, your prior guidance was up low to mid-single digits off of last year's $83 million. Since then, you've done, as you mentioned, three acquisitions. So, could you break out for us the outlook for the base business, is it still low to mid-single's g... | Yeah. I -- I think as of this point, it's -- it's, you know, prior leaning more toward the higher side of that low to mid. You know, it's -- the December quarter is such a small quarter in the full year. And you know, we've -- we've done -- I think the team has done a great job of organizing events to -- to supplement,... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
5172df8bf482a168b5651435d63844fd | You mentioned, your lack of boat shows this year and it was very o -- obviously very helpful in terms of the cadence for your comps but I'm curious how you think about, you know, the impact of boat shows or lack of thereof in terms of March versus June quarter. Could there be sales that typically occur in the March qua... | I -- I -- I will jump in a little bit right there. You know, Joe, thanks -- thanks for the question. You know, the boat shows -- I've said it many times, I'm not a big fan of them. There really is the second biggest expense on our P&L. And when you go to a boat show, you kind of level the playing field for subpar deale... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
3ad27d3af3deb52654d2beb637573761 | You mentioned January was looking good. If you want to add any color. I mean, our comps kind of in line with what you saw in Q1 or any slowdown at all? | Well, I mean, you know, I -- I would just tell you that -- that believes or, you know, we keep waiting for that day where lead starts to slow down. Jack, you -- you can expand on it a little bit more probably than I can on the -- on you know. But it's -- it's definitely -- go ahead.
No. I'm just going to say, if you -... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
cd40f11554462b7d63aa3d45abe2c00a | I think, in -- in the press release you said that the combined benefits from the three acquisitions you made is about $125 million in annualized revenue. I think that's on a 12-trailing month basis. Can you give us a sense of what that looks like in -- in fiscal year '21? Are you assuming that kind of grows in that mid... | Yeah. I -- I would say that is on a -- on a full-year basis and -- and if you're looking at -- that's probably something around at $100 million mark for the contribution this year. | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
ef9462b8045e5b0e076a8ef6d90d856b | I noticed that -- that used boats or preowned boats grew about 17% in the quarter while everything else grew 30%, 40% year over year. Any commentary there on just the availability of preowned products and maybe what you're doing to -- to gain access to inventory there? | Yeah, yeah. I mean, that has really -- Anthony, I was just going say that's really for you.
Yeah. It's -- it's something like that we -- we focus on daily but, you know, we employed employees that are buyers and buyers only. That's all our job is to do is to buy boats. So, it -- it is a -- a challenging part to contin... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
f7de474b6e1348107e14d019a2fc0825 | Maybe just talk about how these stand-alone service centers are -- are contributing and maybe how -- how do you think about that business over the next 12 months? | You're right out there again, that's an Anthony question. But I mean, you -- you can see in the numbers, we -- we start -- we started -- we saw a -- a good increase in imports and service and, you know, obviously some of that is connected to that. Anthony, I mean, you have any like more day-to-day operational comments?... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
1f8cbc2ad3675cede03607b1b479b92b | Hey, good morning. Good morning, everyone. Really I only have two questions. My first question is, you talked about some of your producer customers, bankruptcies, and then you talked about just overall producer bankruptcies industrywide. Can you provide a little more details of your customer credit quality and what pro... | Yes, sure. Hey, Elvira, this is Heath. I'll elaborate a little bit more. I think look virtually really all of our material contracts that we have with customers we do believe are protected just via the dedication language. And as we've seen recently in some of the proceedings gathering contracts or dedications that are... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
fe8297e5cbeacb89eed6457b6e6515fb | Okay, thank you. That's helpful. And then just my next question is just around asset sales. You've talked about asset sales in the past, and I know things may have slowed given the environment we're in with COVID. But just wondering if there is any update there on any discussions you're having? What you're seeing out t... | Yeah. Look, I would describe it generally a slow. I think there continues to be a large degree of interest in the -- our assets, particularly those in the, more in the core areas. But I think what we're seeing here, I think people fundamentally get it. They understand that we're in really good areas of really good rock... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
34d1125489f8fa2ed0c4d9026c1a0ce3 | Hilton, I was hoping you could discuss the commodity cost outlook, as you look out to 2021, particularly on the aluminum side? I know you won't get into guidance territory, but just any conceptual thoughts would be helpful. And if we do see sustained higher commodity costs, can you discuss your willingness to potential... | Yeah. Dara, that's a really good question. I mean, in previous calls like this, I've spoken about the fact that we engage in contracts with aluminum can suppliers from time-to-time to fix some of our aluminum costs and we've done a little bit of that for 2021. Obviously, we monitor aluminum costs every morning and we'v... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
0201e0a956222392734c7f8511f647e6 | For me, I'd like to ask about the seltzer category. Specifically, you made some comments recently at your Analyst Day. We could get some news here, either on the alcohol side or even non-alcohol side. I know it's a big decision and certainly not one where you want to be holding to any sort of timeline that Wall Street ... | I think that our position there is still much the same as we indicated on our last call. We are reviewing -- they're very separate. If you go to the non-alcoholic side, it would be an energy product, obviously. If you go to the alcoholic side, you'd be then competing with all the other colleagues there, the White Claw ... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
1d5873be26b40d7882e9af0b4961fa14 | Thank you. Good afternoon there. I was hoping if you can comment on the inventory levels at the bottlers in light of, obviously, with the pandemic. And obviously not to take away from your strong volumes, did the bottlers decide to take more inventory in the fourth quarter in January and also driven by your innovation.... | So where we are Andrea, is in an interesting territory because you can see that our sales are growing, I think, quicker than we had expected that they would and we are doing everything we can to service our bottlers and get product to our bottlers, so they can service the retail trade. Having said that, I'm pretty conf... | direct | [
"direct",
"intermediate",
"fully_evasive"
] | A |
13b269fc9e4df20694999082ee354c95 | I guess, I'm going to try to cheat and ask a short follow-up and then another question. I guess on the follow-up, what prevents you from working more with the Coke system in procuring aluminum and manufacturing in general, so that you have a bit more of sharing of ability to supply bottlers? And second separate questio... | Let me start, Mark. In terms of working with the Coca-Cola bottlers and working with the Coca-Cola system on procurement of cans, we're doing what we can to produce within the Coca-Cola network. Obviously, that's something that we like to do, because it reduces shipping costs and improves efficiencies. But there are a ... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
5e24496942da990e39a822d0f5c9a9c6 | Hey guys. Good afternoon. Rodney, I just wanted to ask on capital allocation. It's been a couple of quarters, I guess, since we've seen some meaningful share repurchase. You talked about the authorization outstanding. Just help us kind of think about your appetite to do more potentially in 2021 and beyond. | I think that what we did was we were quite active in the market, and then we saw an increase in uptick in the share price. And so we just sort of sat patiently, and that has moved forward. But again, as part of, I think, our own just review of our own opportunities and what we want to do, we've sort of been a bit patie... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
761ec5dcf66ab90ab5109357012ddc64 | I was intrigued by your comment, I think you said you were going to get to the mid-80s on an occupancy level by the end of 2022. And I was just hoping you could talk a little bit more about the signed leases not commenced offset by the rollovers and the known vacates that you have. And I guess how much sort of speculat... | Well, certainly, Steve, first of all, we're focused on our leased percentage, right, and retention of existing tenants, which will drive our future occupancy. We are -- right now, our Manhattan office is 87% leased, and we do expect a higher lease percentage in the first quarter. But of course, the occupancy, as I said... | intermediate | [
"direct",
"intermediate",
"fully_evasive"
] | B |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.